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h i g h l i g h t s
 Management of patients with cancer proved challenging during the COVID-19 pandemic.
 Delivering standard bone care to cancer patients has often not been possible.
 Alternative options, with reduced hospital attendance, have been sought.
 A questionnaire explored solutions for continued provision of bone support.
 This paper provides guidance for optimisation of bone health during COVID-19.
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a b s t r a c t
Optimum management of patients with cancer during the COVID-19 pandemic has proved extremely
challenging. Patients, clinicians and hospital authorities have had to balance the risks to patients of
attending hospital, many of whom are especially vulnerable, with the risks of delaying or modifying cancer treatment. Those whose care has been significantly impacted include patients suffering from the
effects of cancer on bone, where delivering the usual standard of care for bone support has often not been
possible and clinicians have been forced to seek alternative options for adequate management.
At a virtual meeting of the Cancer and Bone Society in July 2020, an expert group shared experiences
and solutions to this challenge, following which a questionnaire was sent internationally to the symposium’s participants, to explore the issues faced and solutions offered. 70 respondents, from 9 countries
(majority USA, 39%, followed by UK, 19%) included 50 clinicians, spread across a diverse range of specialties (but with a high proportion, 64%, of medical oncologists) and 20 who classified themselves as
non-clinical (solely lab-based). Spread of clinician specialty across tumour types was breast (65%), prostate (27%), followed by renal, myeloma and melanoma.
Analysis showed that management of metastatic bone disease in all solid tumour types and myeloma,
adjuvant bisphosphonate breast cancer therapy and cancer treatment induced bone loss, was
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substantially impacted. Respondents reported delays to routine CT scans (58%), standard bone scans
(48%) and MRI scans (46%), though emergency scans were less affected. Delays in palliative radiotherapy
for bone pain were reported by 31% of respondents with treatments often involving only a single dose
without fractionation. Delays to, or cancellation of, prophylactic surgery for bone pain were reported
by 35% of respondents. Access to treatments with intravenous bisphosphonates and subcutaneous denosumab was a major problem, mitigated by provision of drug administration at home or in a local clinic,
reduced frequency of administration or switching to oral bisphosphonates taken at home. The questionnaire also revealed damaging delays or complete stopping of both clinical and laboratory research.
In addition to an analysis of the questionnaire, this paper presents a rationale and recommendations for
adaptation of the normal guidelines for protection of bone health during the pandemic.
Ó 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

and a few on denosumab. [7–12] For metastatic breast cancer,
metastatic prostate cancer, and multiple myeloma there are data
to support dosing zoledronic acid every 3 months at presentation
of bone metastases [10,11] and the optimal dosing for denosumab
is evolving [9]. The key study endpoints have been skeletal related
events, or symptomatic skeletal related events, but the potential
reduced risk of osteonecrosis of the jaw, as well as other toxicities
and financial aspects, have been of great interest with less frequent
dosing [13,14].
There is strong evidence that when bisphosphonates are
absorbed by bone, they reside in bone for many months or even
years and remain active in suppressing resorption [15]. However,
denosumab suppression of resorption falls off much more rapidly
on drug cessation and this has led to concerns about the rebound
effect in bone resorption and increased vertebral fracture risk.
The risk of denosumab associated rebound bone resorption raises
concerns when considering alternative dosing intervals in the setting of COVID19, since clinicians cannot be certain about access to
future dosing. However, other measures can be taken, eg a switch
to bisphosphonates [16].
As well as their use in the palliation of metastatic bone disease,
for postmenopausal women with early breast cancer, the value of
bisphosphonates in the adjuvant setting is now recognised with
many countries using this approach to reduce the occurrence of
bone metastasis [17].
It has long been recognised that, otherwise successful cancer
treatments can have a negative impact on bone composition and
density, resulting in bone loss, potentially leading to osteoporosis
and fragility fractures [18]. This cancer treatment induced bone
loss (CTIBL) is especially associated with hormonal treatments
such as GnRH analogue, aromatase inhibitors in breast cancer
and androgen deprivation therapy in prostate cancer [19,20]. International guidelines in both breast cancer [21] and prostate cancer
[22], are in place for the use of bone targeted agents, principally
bisphosphonates and denosumab, to prevent bone loss and subsequent osteoporotic fracture in this setting and there was a clear
potential for these treatments to also be negatively impacted during the pandemic.
In order to better understand the impact of the coronavirus on
such patients, on the professional healthcare workers who care for
them and on the many linked research programmes, and how
these issues are approached in different parts of the world, the
Cancer and Bone Society (CABS) held a special webinar symposium
as part of (and in association with) a virtual meeting of the American Society for Bone and Mineral Research (ASBMR) in July 2020
entitled ‘COVID-19 and managing bone in patients with all stages
of cancer’. Recognising that the clinical management of patients
with cancer has been dramatically affected by the COVID-19 pandemic, the CABS/ASBMR Webinar presenters outlined challenges
and solutions for bone care in the setting of cancer and COVID19. The session, which was attended by an international audience,

1. Introduction
Patients suffering from cancer are especially vulnerable to
COVID-19, often by virtue of their age, as well as from their disease
or its treatment [1]. Furthermore, because of the reluctance of
some patients to access care during the pandemic, we are now
observing a rise in late cancer diagnosis. The need to protect such
patients from exposure to the virus (for example by limiting their
attendance at hospitals) has had a huge impact worldwide on the
patterns of delivery of cancer care since March 2020. Key changes
have included a major increase in the use of remote consultations
(eg telephone or video rather than face-to face), changes to oral
systemic therapies taken at home whenever possible, rather than
agents administered by iv or subcutaneous injection (requiring a
hospital, clinic or general practitioner (GP) visit), the need for
social distancing and/or wearing of personal protective equipment
when patients do attend hospital and restrictions preventing carer/
relative support for patients attending hospital.
Those whose care has been significantly impacted by COVID-19
include cancer patients suffering from the effects of cancer on
bone. Bone metastases are very common, occurring in 65–75% of
patients with advanced breast cancers as well as approximately
80% of patients with advanced prostate cancer and 17–64% of
patients with advanced lung cancer [2]. These cancers are very
common, hence large numbers of patients are potentially
impacted. Multiple myeloma which originates in the bone marrow
causes extensive bone destruction and, while distinct from metastatic bone disease [3], there are parallels in the management of
these conditions, for example in the treatment of resulting skeletal
complications. Often termed skeletal related events (SREs), these
include significant bone pain requiring radiotherapy, bone fractures often requiring surgery, hypercalcaemia, and spinal cord
compression often requiring emergency need for radiotherapy
and/or surgery [4,5].
Recent advances in anti-cancer systemic therapies, particularly
in advanced breast, prostate and lung cancers, have resulted in
patients living longer, with a resultant requirement for continued
and longer management of their metastatic bone disease to optimise quality of life. It is in this field where bone targeted therapies
have revolutionized the treatment of metastatic bone disease, in
particular the bone resorption inhibitors including bisphosphonates [6] and denosumab [7]. In the metastatic setting, although
orally administered agents are available, most bisphosphonates,
dosed for bone metastases, require iv administration with the frequency of dosing dependent upon the individual bisphosphonate
used. In the case of denosumab, for bone metastases this is typically administered as a subcutaneous injection of 120 mg once
every 4 weeks. Although COVID-19 has accentuated consideration
of less frequent treatments involving hospital attendance across
medicine, even before the pandemic, there has been a range of
studies relating to less frequent administration of bisphosphonates
2
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subsequent additional answer box), these replies were interpreted
manually for inclusion within this publication.
The survey questionnaire is available within the supplementary
data section of the publication.

included presentations covering management of bone in early and
advanced cancer, as well as a question-and-answer session for
interactive dialogue with the Webinar attendees. Following the
Webinar, a questionnaire was sent out to all attendees to better
evaluate how the pandemic has impacted their clinical and
research programmes. This paper presents the questionnaire
results as well as recommendations for adaptations of standard
treatment guidance during the pandemic.

2.2. Setting
The link to the survey was distributed internationally via the
CABS organisation by e-mail and also to all who attended the webinar symposium (including members of ASBMR). There was no
restriction on who could return a completed questionnaire.

2. Methods
2.1. Questionnaire design and distribution:

2.3. Ethical considerations
The questionnaire was constructed within ‘Google Forms’,
which allows on-line completion and use of the integrated analysis
tools. The questions within the survey were initially created by a
subset of the authors of this publication, and circulated, via a
shared folder on Google Drive, to the members of the CABS Board
who span a range of countries of residence and are internationally
respected authorities in the field of cancer and bone. These reviewers of the survey in the construction phase include a wide range of
perspectives in the field of cancer and the skeleton including clinical management of patients, clinically-based research and preclinical, lab-based research in bone oncology. Each member of
the CABS Board had the opportunity to comment on each question
at each iteration. Suggestions were incorporated into the questionnaire form and, following a total of three successive iterations of
this process, the completed survey was tested/piloted by two clinicians, not part of the original design team, to ensure that it was
clear and well understood. The questionnaire was designed so that
it would take a maximum of 20–30 min to complete.
The final questionnaire contained 45 questions of which 40
were addressed towards staff working clinically and 5 were directed towards both clinical and non-clinical staff members. Where
respondents stated that they were non-clinical, they were directed
towards a separate section at the end of the questionnaire. The
form encompassed a range of question types from multiple choice
questions through to yes / no questions and strongly agree /
strongly disagree answers. In cases where the respondent replied
with ‘‘other” a box was provided for text response of answers.
Some questions were mandatory.
The questions, which were intended for professionals in cancer
and bone and not patients, inquired into the recipient’s area of
work, the sector they were involved in, the effect of COVID-19
upon the treatment and bone-imaging choices made, the effects
of the COVID-19 pandemic upon how patients are consulted within
clinics and the effects of the COVID-19 pandemic upon staff
recruitment and training within the institutions as well as the
effects of COVID-19 on basic, translational and clinical research.
The questionnaire was uploaded to Google Drive on 19th July
2020 and the link was distributed by email immediately after the
above CABS symposium and a reminder was sent out after two
weeks. Responses to the survey accumulated within the period
19th July – 8th October 2020 at which point the responses were
analysed. As responses were received from global specialists, the
responses reveal the effects of COVID-19 upon cancer treatment
within countries at different phases of the first wave of virus
infection.
The data analysis tools within Google forms were used to provide an overview of the responses in terms of large-scale distribution of replies (both as pie charts and as histograms). The analyses
and initial drafting of the report was carried out by an author not
involved with clinical management. Where questions asked for
more individual or in-depth responses (or provided the possibility
of providing ‘‘other” answers within a drop-down menu with a

The survey respondents were assured that their responses
would be anonymised and that no data would be shared which
could be used to identify the individual responders.
3. Results
3.1. Respondents and demographics
In total, there were 70 respondents, including 50 clinicians and
20 who classified themselves as non-clinical (solely lab-based).
These were spread across a diverse range of specialisations within
the field of bone oncology. Two clinicians dropped out after the
first two questions, one in orthopaedic surgery and the other in
radiology, probably because many of the following questions
related to physicians giving systemic therapy. Although not
mandatory, 54/70 (77%) respondents provided their email address.
There would be no reason to expect duplication and, since a high
proportion (77%) were known to be not duplicated, the potential
of an effect due to multiple entries is very small. Of the clinicians
who completed the survey, 87.5% were senior doctors and 12.5%
were trainees. Since no limit had been placed upon the distribution
of the questionnaire (indeed respondents were encouraged to
involve other colleagues) and since not all respondents provided
email addresses, it is not possible to define the response rate as
the denominator is not known.
Respondents who provided information on the country in
which they practice revealed coverage within Europe, USA/Canada
and Asia with the USA providing the most responses – (see Fig. 1a).
In terms of the respondent’s area of work, the predominant field
was listed as ‘‘Medical Oncology” (responsible for 64% of replies)
and ‘‘clinical / radiation oncology” was the second most prevalent
response (see Fig. 1b). The majority of respondents (90%) worked
within academic institutions with 10% of respondents working
within non-academic healthcare institutions.
Clinicians responding to this questionnaire worked in a wide
range of tumour types with breast cancer being the most prominent, followed by prostate cancer, renal cancer, myeloma, melanoma and lung cancer (see Fig. 1c).
3.2. Effects upon patient care
3.2.1. Effects of COVID-19 upon tumour imaging
Imaging is critical to management of patients with established
or suspected bone metastases for which patients need to attend
a medical setting. Across all respondents, 58% reported delays to
routine CT scans (Fig. 2a), 47.9% reported a delay in carrying out
standard bone scans (Fig. 2b) and 45.8% reported delays in MRI
scans due to COVID-19 (Fig. 2c). Delays appeared to be in respect
of routine care and not for emergency needs, such as spinal cord
compression.
3
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Fig. 1. Demographic data Area of work and global distribution of questionnaire respondents. (A) Country of practice of the respondents to the survey – 49 responses. Global
distribution of respondents – encompassing Europe, Asia and America / Canada. (B) Area of work of the respondents – 50 responses, (C) Cancer types treated by the clinician
respondents – 47 responses.

Fig. 2. Effect of COVID-19 upon tumour imaging and radiotherapeutic treatments of bone cancers: The effects of COVID19 upon tumour imaging and use of radiotherapies for
bone cancers was assessed using a series of questions. (A) Have there been delays to routine bone imaging such as CT? – 48 responses, (B) Have there been delays in getting
bone scans due to COVID19? – 48 responses (C) Have there been delays in getting MRI scans due to COVID19? – 48 responses, (D) Has there been an impact on palliative
external beam radiotherapy at your centre due to COVID19? – 48 responses, (E) Has there been an impact upon access to stereotactic radiotherapy at your centre due to
COVID19? – 47 responses and (F) Has there been an impact upon access to iMRT for small volume bone metastases at your centre due to COVID19? – 47 responses.

Reported delays in bone scans ranged from 1 to 2 weeks in
about 50% of responses, to up to 2–3 months for the remainder
of the respondents. The average delays to MRI scans followed a

similar pattern with approximately 50% of respondents reporting
delays of 1–3 weeks and the remaining 50% reporting delays of
up to 2–3 months. The majority of the respondents indicated that
4
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affected as palliative care patients need to have face-to-face assessments. There remains concern over access to palliative care services during the pandemic.

these delays were not uniform across sites within their area of
practice.
It should be noted that delays could be due either to a delay in
scanning and reporting following scan request to radiology or a
delayed scan because clinicians had been asked to change normal
practice and request these less frequently in the pandemic. Text
responses in the questionnaire suggested that both sources of delay
were often applicable. Overall, during the first 4 months of the pandemic, 50% or more of the respondents experienced delays in
obtaining imaging studies for their patients with bone metastases.

3.2.2.4. Bisphosphonates and denosumab. The survey and the webinar have highlighted the variety of practice across countries in the
delivery of bone-targeted agents: home or office-based delivery of
bisphosphonates or denosumab vs hospital administration.
Nevertheless, it is clear that COVID-19 has had a significant global
impact upon the treatment of metastatic bone disease using
bisphosphonates or denosumab. Decreased administration of i.v.
bisphosphonates and denosumab was reported by 94.6% and
78.8% of respondents, respectively (see Table 1). The reduced
administration of i.v. bisphosphonates in this study was accompanied by an increased use of home-administered oral bisphosphonates (as reported by 76.5% of respondents). Thirty three
respondents answered the question of whether denosumab use
had increased (7 respondents) or decreased (26 respondents) during the pandemic. From the textual responses, decreased use of
denosumab appears to be related to the logistics of use of
chemotherapy suites which were at reduced capacity with other
treatments receiving priority (including curative chemotherapy).
There was also clear concern as to the possible rebound effect after
stopping denosumab which needs to be avoided, possibly by
replacing with a bisphosphonate. Those that suggested an increase
in denosumab use may have been in countries where IV bisphosphonates were routinely used and where denosumab could be
administered without use of chemotherapy infusion suites.
These alterations to the administration of oral and i.v. bisphosphonates and subcutaneous denosumab were accompanied by
increased use of speciality clinics (16–18%) to ensure rapid patient
throughput and increase in home administration (up to 15%) with
one report of a ‘‘drive through” administration.
Treatment of bone metastases arising from prostate cancer has
increasingly involved the use of 223Radium (in those countries
where it is available), a short range alpha-emitting radioactive isotope of radium which is taken up into bones in the place of calcium, and which therefore specifically targets bone-resident
cancer cells. Of the 44 respondents to the question on the use of
223
Radium during the pandemic, 30 indicated that they did not
treat prostate cancer and of the remaining 14 respondents who
treated prostate cancer, 4 reported no change, with 6 reporting
decreased use and 4 reporting increased use of 223Radium.
Treatment of bone metastases and myeloma bone disease with
bisphosphonates and denosumab has been significantly impacted,
but alterations to use and scheduling of iv and oral bisphosphonates and denosumab have been implemented to optimise patient
care (see Table 3)

3.2.2. Effects of COVID-19 on the treatment of patients with metastatic
bone disease and multiple myeloma
Treatment of bone metastases and multiple myeloma involves
radiotherapeutic and surgical approaches as well as the use of
bone-targeted agents (including oral and i.v. bisphosphonates,
denosumab and, in the case of prostate cancer, 223Radium treatment). With the exception of oral bisphosphonates, all of these
treatments normally require clinic or hospital attendance. Depending upon the therapeutic agent in question, dosing may range from
every 4 weeks to less frequently out to every 3 – 6 months.
3.2.2.1. Radiotherapy and delays due to COVID-19. Effects of COVID19 upon radiotherapy (palliative external beam radiotherapy for
bone pain – Fig. 2d, stereotactic radiotherapy – Fig. 2e, and iMRT
for small volume bone metastases – Fig. 2f) was assessed, with
14.3–31.3% of respondents reporting an impact upon the provision
of this radiotherapy (Table 1). Reported delays to palliative external beam radiotherapy ranged from 1 to 2 weeks to a month and
when respondents were asked about how treatments were
impacted, delay of treatment was commonly cited. The number
of fractions which would normally be given for palliation were
reduced in some institutions, eg a single fraction for bone pain,
rather than multiple fractions. For stereotactic treatment, whilst
some respondents said there was no delay, this may have been
partly because adaptations were made to the sequence of treatments. For IMRT, the high level of ‘don’t knows’ is probably
because most respondents were not radiation oncologists. Delays
in radiation therapy to bone metastases were reported in up to
one third of respondents with reports of decreases in number of
radiation fractions occurring to minimise clinic visits.
3.2.2.2. Prophylactic surgery. Prophylactic surgery is frequently
employed for patients with metastatic bone disease at risk of
developing bone fractures. Alterations to the use of prophylactic
surgery for bone pain were reported by 34.8% of the 46 questionnaire respondents, with delays frequently cited as well as cancellation of prophylactic surgery during the initial intense phase of
COVID-19 infections. Some respondents reported increased thresholds being employed for performing prophylactic surgery as well
as cancellation of non-essential operations during the peak of the
pandemic. Comments included ‘surgery delayed unless absolutely
necessary’, ‘prophylactic surgery was stopped for 4 months, now
resumed’, ‘All non-emergency surgeries were postponed’. The
impact of a possible increased future incidence of pathological
fracture remains to be determined and is of concern.

3.2.3. Impact upon use of adjuvant bisphosphonates:
Adjuvant bisphosphonates are increasingly used for the reduction/prevention of bone metastases in breast cancer. Overall 72%
of 47 clinicians responding reported that adjuvant bisphosphonates were normally used within their patient populations. Of
these clinicians, 66% (23 respondents) reported that COVID-19
had impacted upon adjuvant bisphosphonate use (Fig. 3). These
alterations to normal use included delays to treatment, delayed
or missed appointments (in some cases due to patients declining
to come in for appointments), reduced clinical availability owing
to the demands of caring for COVID-19 patients and the switch
from i.v. to an oral route of administration. There appeared to be
a number of assessments that postponing adjuvant treatment represented a lower risk than exposing patients to the higher risks of
hospital attendance which was necessary for iv zoledronic acid
infusion. In some cases, adjuvant bisphosphonates had been
restarted after 4 months. Revised guidelines in the UK imposed

3.2.2.3. Palliative care. In terms of the management of bone pain,
access to palliative care for bone pain was judged to be negatively
impacted in 30% of the clinicians questioned. Of those, some
reported clinic locations were closed during the height of the outbreak and there were reports of very poor access to community
palliative care services in many areas (but not all). Clinician access
was mainly via
telephone, with a significant decline in home and face-to-face
visits and it was felt that the quality of assessments may have been
5
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Table 1
Effects of COVID-19 upon bone-targeted treatments within metastatic disease:
Treatment Modality

Impacted

Denosumab Administration

43.8%

I.V. Bisphosphonate Administration

68.8%

Oral Bisphosphonates

14.9%

223

18.2%

Radium Administration

Increased 21.2%
Decreased 78.8%
Increased 5.4%
Decreased 94.6%
Increased 76.5%
Decreased 23.5%
Increased – 40%
Decreased – 60%

Not-Impacted

Unsure

41.7%

14.6%

20.8%

10.4%

59.6%

25.5%

13.6%

68.2% recipients don’t treat prostate cancer

Fig. 3. COVID-19 and Bone Health: The effects of COVID19 upon bone health was assessed via the following questions: (A) Are adjuvant bisphosphonates used for patients
with breast cancer at your centre? – 47 responses. Among respondents who answered ‘‘yes” the following questions were then asked: (B) If yes, has this been impacted by
COVID19? – 47 responses. (C) Has bone health monitoring e.g. bone density DEXA scans, been impacted by COVID19 at your centre? – 47 responses. (D) Has your treatment of
cancer treatment induced bone loss been changed due to COVID19? – 46 responses, and (E) Have you changed your antiresorptive therapy regimens for cancer treatment
induced bone loss due to the COVID19 pandemic? – 47 responses.

owing to COVID-19. Within CTIBL, up to 44% of clinicians reported
a change to the anti-resorptive therapies they administer during
the COVID-19 pandemic.
The effects of COVID-19 upon treatment of osteoporotic fractures produced a similarly mixed response albeit with slightly less
concern about the long-term impact of COVID-19. These responses
may reflect the timescale over which the respective medical conditions require treatment and the hopes that a treatment (such as a
COVID-19 vaccine) might return a degree of normality to treatment in future and these patients could subsequently be treated
when more routine services were available.
Long-term bone mass and risk of osteoporosis was regarded as
not highest priority as there could be a return to treatment postpandemic.

by COVID-19 suggested not giving adjuvant bisphosphonates during the pandemic.
Adjuvant bisphosphonate therapy has been significantly disrupted because postponing was thought to be lower risk than
potential exposure to COVID-19.
3.2.4. Impact on bone mass and osteoporosis (CTIBL).
DEXA scans are employed to monitor bone health within both
cancer patients and patients with benign conditions such as osteoporosis. These are done relatively infrequently (eg annually or
every 2 years). COVID-19 appears to have substantially impacted
upon the use of DEXA scans with 63.8% of respondents reporting
a reduced frequency. Many clinicians reported the reduced availability of DEXA scanning, as well as delays, in many cases of a 3–
4 month duration (though this may be equivalent to saying that
scans had not been done at all up until the questionnaire was completed). Long term bone health was probably regarded as low priority compared with many other needs and, when treatment was
given, this was increasingly without repeating the DEXA scan.
Common alterations reported included a move to the use of oral
bisphosphonates (eg ibandronate) and away from i.v. infusion and
reduced frequency of infusion as well as cancellation of treatments

3.2.5. Patient follow-up and access to pharmacies:
The adoption of remote follow-up of patients varied widely
between respondents and when this question was further pursued
in terms of timing, many centres adopted remote follow-up of all
patients at the height of the first wave of COVID-19 and then
moved more towards face-to-face assessments later, once the peak
of infection had receded. For many countries, the first wave had
6
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Fig. 4. Follow-up and management of patients with bone metastases: Within the questionnaire 85% of respondents indicated that their patients did have non face to face
consultations. Further questions were asked relating to patient care and treatments including (A) For non-face to face meetings have you been using video conferencing,
telephone or both? – 45 responses, (B) Has there been increased use of local provider(s) for local care? – 47 responses, (c) Has the use of prophylactic surgery for patients at
risk of fracture been affected at your centre? – 46 responses, (D) Has access to palliative care for pain control been affected in your centre due to COVID19? – 47 responses, (E)
Has access to outpatient pharmacies and associated medications been impacted by COVID19 for your patients with bone metastases? – 47 responses, and (F) Have you
noticed a change in your opiate for bone pain prescribing pattern during COVID19? – 48 responses.

3.2.7. Effects on cancer and bone research and trainees:
COVID-19 has clearly also had a major impact upon bone
metastasis and bone health research. In our study, 59.3% of 59
respondents reported a negative impact of COVID-19 upon the progress of bone-related clinical trials (see Fig. 5). Indeed, this interruption to trials evoked the strongest reaction of all the
questions. Many respondents reported reduced recruitment of
patients to clinical trials, and the suspension of all non-COVIDrelated clinical trials was also frequently mentioned as a major
concern. Issues with patient sampling and data capture were also
highlighted. In many cases, trial suspension seems to have been a
temporary measure as a significant number of the respondents
reported (at the time of the questionnaire) the resumption of
patient recruitment following the peak of the first wave of the pandemic. However, the impact of the second wave on non-COVID-19
clinical research, is of growing concern.
Cancer-orientated laboratory research appears to have been
hugely impacted by the COVID-19 pandemic with 60.7% of
respondents reporting major inhibition, often with research having to be scaled back to only ‘essential’ work. The impacts
reported commonly included the closure of laboratory spaces
for all but COVID19-related research. The reduction in research
activity was reported as easing slightly, however a frequent
approach within research departments has been to re-open gradually with less than full capacity staff members and many
respondents reported departmental re-opening at 10%-50% capacity. The delays to bone-related research have been particularly
felt within longer timescale experiments, especially work involving animals, where delays have been substantial and many more
sophisticated planned experiments have been impossible to
pursue.
Effects upon trainees within the cancer and bone field have
been particularly acute with 78.8% of respondents reporting
decreased access to training as well as reduced training hours,

already subsided when the questionnaire was completed. Nonface-to-face methods of follow up were commonly adopted within
85.1% of the respondents (Fig. 4), with 53.3% reporting the use of
telephone follow-up only, 6.7% video conferencing only and 40%
reporting use of both methods. In addition, just over half of respondents (57.4%) reported the increased use of more local care providers, to decrease outpatient attendance either at the hospital or
large oncology centre.
Only 17% of questionnaire respondents felt that there was a
negative impact of COVID-19 on access to medication via outpatient pharmacies, the main issue being the closure of hospital pharmacies with redirection of patients towards local pharmacies.
Alterations to the prescription of opiates occurred in only 8.3% of
respondents and this appears to have mainly involved the
increased dispensation of opiate medications by GPs and palliative
care teams and less by hospital pharmacies.

3.2.6. Other concerns
For the question relating to reimbursement, 60% of respondents
said this was not relevant, which probably means they had
national health services such as the NHS in the UK. Of the remaining 40% of the respondents who were Yes/No (as to whether billing
was an issue), only 21% replied ‘‘yes” but it is noteworthy that a
significant proportion of these respondents were from within the
USA.
Questions relating to the effect upon SRE incidence in patients
with bone metastases revealed a disparity in answers, with
roughly a third of respondents stating it would probably have no
significant long-term effect upon SRE incidence. However, this
was at a time when the first wave had subsided and care was
returning to something like normal. It is likely that views will be
very different with greater concerns during and after second and
subsequent waves.
7
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Fig. 5. COVID-19 and Bone Research: Effects of COVID19 upon bone research was addressed by asking the following questions: (A) Have bone directed clinical trials been
affected at your institution during COVID19? – 59 responses, (B) Have bone oriented or cancer oriented labs been affected at your institution during COVID19? – 66 responses,
(c) Have the trainees in the cancer and bone field experienced significant changes to their learning opportunities during COVID19? – 66 responses, and (D) Have there been
financial constraints to cancer and bone research funding during COVID19? – 61 responses.

the healthcare systems of every country worldwide. The present
questionnaire results reveal the effect of COVID-19 upon the clinical management of patients with metastatic bone disease and
CTIBL, as well as the wider impacts upon the field of bone research.
In terms of the clinical management of such patients, all aspects
of treatment have been impacted from bone scans, treatment for
metastasis and the use of therapeutic agents in the adjuvant setting to prevent the recurrence of bone metastasis. Bone scans
and radiotherapies have been administered less frequently with
serious delays to normal standards of care. There has been a clear
shift towards oral administration of bisphosphonates and away
from i.v. infusion, enabling a reduction in outpatient visits for
patients. The use of telephone and video conferencing has enabled
the follow-up of patients to continue without the need for face-toface contact. However, as the length of the pandemic has now
exceeded 1 year, patients may be suffering from lack of face-toface contact with their clinical team, with psychological effects.
Other aspects of coping during the pandemic were raised by
responses to the questionnaire. Clearly there was a delay in standard treatment and some delays became built into modified standard treatments. Greater flexibility was shown in the order in
which treatments were carried out, where this could assist in solving logistical problems. It is also clear that administrative and
logistical issues arose because normal procedures were continually
needing to be changed and staff were having to adapt to the new
‘norm’.

increased reliance upon online training, reduced lab- and campusaccess and greatly reduced face-to-face interactions with peers,
with less supervision and mentorship. This has been especially
problematical for researchers trying to complete PhD and postdoctoral research. The funding of bone research was raised as a concern by 44.3% of respondents with notable effects of COVID-19
upon the level of funding for non-COVID based research, fewer
openings for submitting grant applications and the consumption
of grant funding via less productive routes owing to the effects of
COVID-19. Many respondents expressed concern for the longterm implications of COVID-19 upon bone research.
4. Discussion:
Of those clinicians and scientists who responded to the questionnaire, analysis of the number of responses to each question
showed that there was strong engagement through to the end of
the questionnaire (see Table 2). There was also a good response
to the opportunities for provision of textual information which,
although anecdotal, painted an informative picture of the impacts
of the pandemic on patients and care systems involving cancer and
bone.
The COVID-19 pandemic has been, and still is, one of the greatest challenges ever faced by the global healthcare and medical
research community. The requirement to reduce face-to-face contact in order to reduce viral transmission rates has placed strain on
8
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Table 2
Most common questions with comments.
Q8. Have there been any delays in getting routine bone imaging such as CT due to COVID19?
What is the average length of the delay?
 2 weeks: 3 out of 25 responses 12%
 2–4 weeks: 11 out of 25 responses 44%
 4–8 weeks: 7 out of 25 responses 28%
 More than 8 weeks: 1 out of 25 responses 4%
 Not specified: 3 out of 25 responses 12%
Q11. Have there been any delays in getting bone scans due to COVID19?
what is the average length of the delay?
 2 weeks: 2 out of 19 responses – 10.5%
 2–4 weeks: 8 out of 19 responses – 42.1%
 4–8 weeks: 5 out of 19 responses – 26.3%
 More than 8 weeks: 2 out of 19 responses 10.5%
 Not specified: 2 out of 19 responses 10.5%
Q12. Have there been any delays in getting MRI scans due to COVID19?
what is the average length of the delay?
 2 weeks: 2 out of 22 responses – 9%
 2–4 weeks: 8 out of 22 responses – 36.3%
 4–8 weeks: 6 out of 22 responses – 27.3%
 More than 8 weeks: 1 out of 22 responses – 4.5%
 Not specified: 5 out of 22 responses – 22.7%
Q13. Has there been an impact on palliative external beam radiotherapy at your centre due to COVID19?
What is an average length of the delay?
 2 weeks: 5 out of 11 responses – 45.4%
 2–4 weeks: 2 out of 11 responses – 18.2%
 4–8 weeks: 0 out of 11 responses – 0%
 More than 8 weeks: 1 out of 11 responses – 9%
 Not specified: 3 out of 11 responses – 27.3%
Q14. Has there been an impact upon access to stereotactic radiotherapy at your centre due to COVID19?
What is an average length of the delay?
 2 weeks: 1 out of 8 responses – 12.5%
 2–4 weeks: 2 out of 8 responses – 25%
 4–8 weeks: 1 out of 8 responses – 12.5%
 More than 8 weeks: 2 out of 8 responses – 25%
 Not specified: 2 out of 8 responses – 25%
Q16. What percentage of your patients with bone metastases have been having remote follow-up?
 0–10%: 6 out of 29 responses: 20.7%
 11–30%: 2 out of 29 responses: 6.9%
 31–50%: 4 out of 29 responses: 13.8%
 51–80%: 6 out of 29 responses: 20.7%
 81–100%: 9 out of 29 responses: 31%
 Not specified: 2 out of 29 responses: 6.9%
Q41. Have bone directed clinical trials been affected at your institution during COVID19?
 Many temporarily interrupted.
 Recruitment halted.
 Difficult to start or plan new trials
 Some trials concluding with reduced recruitment
 Issues with patient sampling
 Issues with data capture
Q42. Have bone oriented or cancer-oriented labs been affected at your institution during COVID19?

 Most labs were closed during lockdown (March to June).
 Ongoing restrictions and reduced capacity after reopening
 Animal experiments especially affected
 Longer timescale experiments almost impossible
 Substantial staffing issues
 Funding issues in terms of grant extensions
Q43. Have the trainees in the cancer and bone field experienced significant changes to their learning opportunities during COVID19?
 Mostly remote learning and interaction, no face-to-face meetings.
 Inability to perform experiments in the labs and delays in completion of doctoral projects.
 Less clinic exposure and face-to-face consultations. More telephone/virtual clinics.
 Trainee redeployment to covid areas.
Q44. Have there been financial constraints to cancer and bone research funding during COVID19?
 Research funding reduced.
 Few grants opening, less non-COVID funding available.What steps are you or your institution taking to compensate for any lapse in training or research projects?
 Possibility to extend doctoral contracts
 Prioritising writing of manuscripts and data analysis.
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Table 3
Cancer and bone: Recommendations for consideration if current management guidance is disrupted during the COVID-19 pandemic (ASCO guidelines are included for breast
cancer, prostate cancer and myeloma and ESMO guidelines for lung cancer and other solid tumours, though it should be emphasised that, as expected, there is a high level of
commonality among guidelines. Therefore, recommended adaptations for disruption caused by the pandemic are intended to guide decisions whichever guidelines are normally
used).
GUIDANCE COMMON TO ALL SOLID TUMOUR TYPES AND MYELOMA
CURRENT GUIDANCE (ASCO, ESMO)
Radiotherapy is one of the main therapeutic approaches to palliate
pain in patients with bone metastasis.
Calcium and vitamin D supplementation (eg, calcium 500 mg and
vitamin D 400 IU daily) has been prescribed or strongly
recommended within clinical trials of zoledronic acid or
denosumab and is recommended within the package inserts of
both drugs.
Orthopaedic surgery (high risk of fracture, metastatic long bone
fracture, spinal cord compression)
Dental evaluation prior to start of zoledronic acid or denosumab is
recommended as invasive dental procedures or ill-fitting dental
appliances during therapy are a common predisposing factor in
cases of ONJ.

RECOMMENDATIONS FOR CONSIDERATION IF ADHERENCE TO
GUIDANCE IS DISRUPTED DURING COVID-19 PANDEMIC
Continue radiotherapy as needed, but consider giving as a single
(not fractionated) dose.
Continue with calcium and vitamin D supplementation.

These situations represent a medical emergency and surgery should
not be delayed.
Maintain dental evaluation if at all possible, or at least
patient/physician visual inspection when dentistry appointments
are not available.

BREAST CANCER
INDICATION

CURRENT GUIDANCE (ASCO)

RECOMMENDATIONS FOR CONSIDERATION IF ADHERENCE TO
GUIDANCE IS DISRUPTED DURING COVID-19 PANDEMIC

Advanced Breast Cancer,
bone Metastases [24]

Patients with breast cancer who have evidence of bone metastases
should be treated with a bone modifying agent. Options include

Patients with breast cancer who have evidence of bone metastases
should be treated with a bone modifying agent. Options include






denosumab, 120 mg subcutaneously, every 4 weeks
pamidronate 90 mg intravenously, every 3 to 4 weeks;
zoledronic acid, 4 mg intravenously every 12 weeks
zoledronic acid, 4 mg intravenously every 3 to 4 weeks

Early Breast Cancer,
adjuvant
bisphosphonates [25]

It is recommended that, if available, zoledronic acid (4 mg
intravenously every 6 months) or clodronate (1,600 mg/d orally)
be considered as adjuvant therapy for postmenopausal patients
with breast cancer who are deemed candidates for adjuvant
systemic therapy

Early Breast Cancer,
prevention of bone loss
[21]

Patients with osteoporosis or who are at increased risk of
osteoporotic fractures based on clinical assessment or risk
assessment tools, bone-modifying agents, such as oral
bisphosphonates, intravenous (IV) bisphosphonates or
subcutaneous denosumab at the osteoporosis-indicated dosage,
may be offered to reduce the risk of fracture. Hormonal therapies
for osteoporosis management (eg, estrogens) are generally
avoided in patients with hormonal-responsive cancers
Additionally, specific populations may be considered appropriate
candidate for bone-modifying agents:
 Premenopausal women receiving GnRH therapies causing
ovarian suppression or with CIOF or who have undergone an
oophorectomy
 Postmenopausal women who are receiving aromatase
inhibitors

 denosumab, 120 mg subcutaneously
- when possible use local or home administration every
4 weeks.
If this is not possible, due to concerns for rebound vertebral fractures, consider change to zoledronic acid 4 mg intravenously every
12 weeks.  zoledronic acid, 4 mg intravenously
- when using intravenous anticancer therapy, continue zoledronic acid dosing if it coincides with anticancer infusions,
dosing every 12 weeks (preferred intervention for most
patients with breast cancer)
- if zoledronic acid infusions are impractical, consider oral bisphosphonates, dosed for bone metastases Clodronate
1200 mg orally daily, Ibandronate 50 mg orally daily
 When no other option is available, consider oral bisphosphonates dosed as labelled for osteoporosis
It is recommended that, if available, zoledronic acid (4 mg
intravenously every 6 months) or clodronate (1,600 mg/d orally) be
considered as adjuvant therapy for postmenopausal patients with
breast cancer who are deemed candidates for adjuvant systemic
therapyWhen infusion therapy is limited, consider zoledronic acid
5 mg once a year
Timely access to DEXA scans to assess BMD may not be possible, but
fracture risk assessment, such as the WHO FRAX score (https://
www.sheffield.ac.uk/FRAX/tool.aspx) should be considered to
assess those at high risk of osteoporotic fracture.
Patients with osteoporosis or who are at increased risk of
osteoporotic fractures, bone-modifying agents, such as oral
bisphosphonates, intravenous bisphosphonates are favoured agents
to avoid the potential interruption of denosumab dosing and
associated rebound fracture risk.
In patients presently receiving denosumab or zoledronic acid
consider off site, drive-through or home administration if feasible.
In patients presently on denosumab (60 mg every 6 months)
consider oral bisphosphonate via telemedicine immediately in
patients at high risk of fracture until they can resume original
therapy.

PROSTATE CANCER
INDICATION

CURRENT GUIDANCE (ASCO)

RECOMMENDATIONS FOR CONSIDERATION IF ADHERENCE TO
GUIDANCE IS DISRUPTED DURING COVID-19 PANDEMIC

Advanced Prostate Cancer –
Bone Metastases [26]

In men with metastatic CRPC (mCRPC), either zoledronic acid
(minimally symptomatic or asymptomatic disease) or denosumab
(disease independent of symptoms) (both at bone metastasisindicated dosages: zoledronic acid, 4 mg iv, 3–4 weekly;
denosumab, 120 mg sc, 4 weekly) is recommended for preventing
or delaying skeletal-related events (SREs).

Patients with prostate cancer who have evidence of bone
metastases should be treated with a bone modifying agent. Options
include
 denosumab, 120 mg subcutaneously
- when possible use local or home administration every 4 weeks.
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Table 3 (continued)
GUIDANCE COMMON TO ALL SOLID TUMOUR TYPES AND MYELOMA

Bone loss due to ADT or
other treatments
affecting hormone levels
[26]

In men with symptomatic mCRPC, Ra-223 is recommended to
extend overall survival.
In men with symptomatic mCRPC and bone pain, radium-223 (Ra223) should be considered for reducing symptomatic skeletal
events and improving health-related QoL.
Systemic therapies for the treatment of mCRPC such as
abiraterone/prednisone, enzalutamide, docetaxel and cabazitaxel
have been shown to reduce SREs, improve bone pain and healthrelated QoL, and/or improve overall survival in mCRPC.
Mitoxantrone has also been shown to improve pain and healthrelated QoL. The optimal sequencing or combination of these
therapies with bone-targeted agents is unclear, and
recommendations to patients should be done in consultation with
a clinician.
There is evidence to suggest harm in the form of increased fracture
risk with the combination of Ra-223 when administered with
abiraterone and prednisone initiation; that combination should be
avoided. Current guidelines do not support concurrent use of Ra223 with other secondary therapies known to prolong survival for
mCRPC.
For men with non-metastatic prostate cancer at high risk of
fracture receiving ADT, denosumab at the osteoporosis-indicated
dosage should be considered to reduce the risk of fracture. In
situations or jurisdictions where denosumab is contraindicated or
not available, a bisphosphonate is a reasonable option. Baseline
bone mineral density (BMD) testing with conventional dual x-ray
absorptiometry is encouraged for men before starting ADT to help
determine fracture risk and to identify those individuals who
would probably benefit from pharmacological intervention.

- If this is not possible, due to concerns for rebound vertebral
fractures, consider change to zoledronic acid 4 mg intravenously every 12 weeks. zoledronic acid, 4 mg intravenously
- when using intravenous anticancer therapy, continue zoledronic acid dosing if it coincides with anticancer infusions, dosing every 12 weeks (preferred intervention for most patients
with prostate cancer)
- if zoledronic acid infusions are impractical, consider oral bisphosphonates, dosed for bone metastases Clodronate 1200 mg
orally daily, Ibandronate 50 mg orally daily. When no other
option is available, consider oral bisphosphonates dosed as
labelled for osteoporosis
If Ra-223 not available, consider external beam or sterotactic
radiotherapy for bone pain and bisphosphonates or denosumab for
reducing SREs and improving health-related QoL (please see above
for recommend options).
Consider using oral anticancer therapies, that have demonstrated a
decrease in SREs such as abiraterone or enzalutamide.

Avoid combination of Ra-223 with other therapies.

Timely access to DEXA scans to assess BMD may not be possible, but
fracture risk assessment, such as the WHO FRAX score (https://
www.sheffield.ac.uk/FRAX/tool.aspx) should be considered to
assess those at high risk of osteoporotic fracture.
If denosumab administration is not possible, consider annual
infusion of zoledronic acid at osteoporosis dose. If this is not
possible, consider oral bisphosphonates at osteoporosis doses

MULTIPLE MYELOMA
INDICATION

CURRENT GUIDANCE(ASCO)

RECOMMENDATIONS FOR CONSIDERATION IF ADHERENCE TO
GUIDANCE IS DISRUPTED DURING COVID-19 PANDEMIC

MGUS, asymptomatic
myeloma (SMM) [27]

Watchful waiting for standard risk SMM.
Clinical trial may be considered for high risk SMM.

Symptomatic myeloma [27]

Intravenous administration of pamidronate 90 mg or zoledronic
acid 4 mg every 3 to 4 weeks, or denosumab 120 mg every
4 weeks
If patients have problems of renal impairment, denosumab is
preferred compared to iv aminobisphosphonates
Treatment with the bone-modifying agents is recommended to
continue for up to 2 years
Continuous use of the agents depends on discretion of physicians

Relapsed and/or refractory
myeloma [27]

Treatment of biochemically relapsed should be individualized. All
clinically relapsed patients with symptoms due to myeloma
should be treated immediately.

Watchful waiting.
Scheduled visits of patients with stable disease can be delayed with
safety. Alternatively, blood examination in local laboratories and
consultation via telemedicine is encouraged.
- Patient and family member education
Disease control is a priority, but consider reducing steroid doses
Options include
 denosumab, 120 mg subcutaneously
when possible use local or home administration every 4 weeks.
- If this is not possible, due to concerns for rebound vertebral
fractures, consider change to zoledronic acid 4 mg intravenously every 12 weeks.
 zoledronic acid, 4 mg intravenously
- when using intravenous anticancer therapy, continue zoledronic acid dosing if it coincides with anticancer infusions, dosing every 12 weeks
- if zoledronic acid infusions are impractical, consider oral bisphosphonates, dosed for bone metastases Clodronate 1200 mg
orally daily, Ibandronate 50 mg orally daily. When no other
option is available, consider oral bisphosphonates dosed as
labelled for osteoporosis
Watchful waiting may be considered for patients with biochemical
relapses, especially for patients with a slow and gradual increase in
the paraprotein level. New onset of end-organ damage features
(CRAB) and a history of aggressive relapse with rapid deterioration
of the clinical presentation should receive next-line treatment
without delay.
Regarding the selection of treatment regimen, orally administered
agents (ixazomib, lenalidomide, pomalidomide, and panobinostat)
should be considered.
(continued on next page)
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Table 3 (continued)
GUIDANCE COMMON TO ALL SOLID TUMOUR TYPES AND MYELOMA
LUNG and OTHER SOLID TUMOUR SITES (except breast and
prostate cancer)
INDICATION

CURRENT GUIDANCE (ESMO)

RECOMMENDATIONS FOR CONSIDERATION IF ADHERENCE TO
GUIDANCE IS DISRUPTED DURING COVID PANDEMIC

Advanced cancer, bone
metastases [28]

Bone targeted agents:
 Start as soon as bone metastases are diagnosed whether or not
they are symptomatic, to prevent SRE, in patients with a life
expectancy greater than 3 months.
 Continue bone targeted agents indefinitely except in patients
with good prognostic features (treated oligometastatic disease, low risk of bone complication, sustained response to systemic oncological treatments)
 Modalities : Bisphosphonates: monthly zoledronic acid
administration during 3–6 months followed by infusion every
12 weeks or Denosumab 120 mg SC monthly administration

Bone targeted agents:
 Start as soon as bone metastases are diagnosed whether or not
they are symptomatic to prevent SRE, in patients with a life
expectancy greater than 3 months.Options include
 denosumab, 120 mg subcutaneously
- when possible use local or home administration every 4 weeks.
- If this is not possible, due to concerns for rebound vertebral
fractures, consider change to zoledronic acid 4 mg intravenously every 12 weeks. zoledronic acid, 4 mg intravenously
- when using intravenous anticancer therapy, continue zoledronic acid dosing if it coincides with anticancer infusions, dosing every 12 weeks (preferred intervention for most patients
with solid tumours)
- if zoledronic acid infusions are impractical, consider oral bisphosphonates, dosed for bone metastases Clodronate 1200 mg
orally daily, Ibandronate 50 mg orally daily. When no other
option is available, consider oral bisphosphonates dosed as
labelled for osteoporosis

cancer drugs and biological therapies during the pandemic [23].
New funding opportunities available for work outside of the field
of COVID-19-related research have been restricted. The recruitment and training of laboratory staff has also been very severely
impacted with reduced face-to-face supervision of students,
increased online training and extension of deadlines necessary
for submission of both grant applications and outputs of work such
as doctoral theses. The overall impact on research into cancer and
bone is likely to be substantial and may be long-lasting.
Despite the promise of effective vaccines, it has become clear
that COVID-19 will remain a serious healthcare challenge well into
2021 and beyond. Providing the best care for patients with cancer
and bone involvement, as well as improving the outlook for such
patients via continued scientific and medical research will be key
challenges going forwards during and following the COVID-19 pandemic. Whilst there is evidence that some normality returned to
this field following the first wave, the severity of the second and
subsequent waves and the effects of more easily transmitted variants, suggest that the issues restricting optimum treatment of
patients with metastatic bone disease or CTIBL will continue for
many months. At that time it will be important to consider,
through new programmes of research, the possible long term
effects of the restrictions caused by the pandemic on patients suffering from the effects of cancer on the skeleton.

There seems no doubt that despite major efforts, optimal treatment of patients with bone metastases has been difficult to achieve
during the pandemic. For many such patients the likely timescale
of restrictions due to the pandemic is of the same order of magnitude as their survival time following bone metastasis diagnosis,
typically 2–3 years. It is possible that a cohort of patients may
not be able to achieve optimum quality of their remaining life
because of the pandemic. However, the unexpected ‘experiment’
in care delivery imposed by the COVID-19 pandemic may uncover
the possibility that our ‘‘optimal” regimens may have been over
treating some patients. In the absence of prospectively designed
studies, it will be challenging to evaluate the impact of COVID-19
on bone specific endpoints. Long-term effects on patients susceptible to CTIBL may also become more significant.
Some care in interpretation of the questionnaire needs to be
emphasised. It represents a particular snapshot in time from a
workforce with special interests in cancer and the skeleton, not
representative of the wider body of practicing oncologists. However, this also has benefits in that the resulting recommendations,
including those in Table 3, are available to all oncologists, including
non-bone specialists. Our purpose is to highlight major effects of
the pandemic and how these can best be mitigated, as perceived
by a group of experts from a range of countries involved in dayto-day care of patients with cancer and its impact on bone. The
respondents were heavily weighted towards oncologists and
mainly medical oncologists. The perceptions of the respondents
may therefore not be representative of those of radiation oncologists, surgical oncologists, haematologists or clinicians managing
benign bone disease.
The above evidence has clearly demonstrated that clinicians
have responded to the necessity, caused by COVID-19, of adapting
normal practice in the treatment of metastatic bone disease and
other scenarios involving cancer and bone. We believe it is useful
to bring together recommendations on how national and international guidelines may be adapted to provide best continuing care,
given the continuing pandemic. These recommendations are contained in Table 3 for breast cancer, prostate cancer, other solid
tumours and multiple myeloma.
In the vital area of research into cancer and bone, there has been
a marked decrease in activity and this seems likely to continue for
many months. This is well documented in a recent Lancet Oncology
article, which demonstrates a 60% decrease in new clinical trials for
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